Cognitive Effects of Nimodipine in Patients With Schizophrenia
| Status: | Recruiting |
|---|---|
| Conditions: | Schizophrenia, Psychiatric, Psychiatric |
| Therapuetic Areas: | Psychiatry / Psychology |
| Healthy: | No |
| Age Range: | 18 - 55 |
| Updated: | 11/10/2018 |
| Start Date: | October 5, 2018 |
| End Date: | October 2019 |
| Contact: | Kristin Bigos, PhD |
| Email: | kbigos1@jhu.edu |
| Phone: | 614-0453 |
This study aims to evaluate the acute effects of nimodipine on cognitive performance in
patients with schizophrenia using a battery of cognitive assessments.The subjects will also
complete a 30-minute structural and functional MRI scan, with the goal of linking brain
activity with working memory performance. Investigators predict that the performance increase
induced by nimodipine will be greater in subjects who carry the A allele for the Calcium
Voltage-Gated Channel Subunit Alpha1 C (CACNA1C) risk single nucleotide polymorphism (SNP)
(rs1006737) in comparison to the response of G carriers.
patients with schizophrenia using a battery of cognitive assessments.The subjects will also
complete a 30-minute structural and functional MRI scan, with the goal of linking brain
activity with working memory performance. Investigators predict that the performance increase
induced by nimodipine will be greater in subjects who carry the A allele for the Calcium
Voltage-Gated Channel Subunit Alpha1 C (CACNA1C) risk single nucleotide polymorphism (SNP)
(rs1006737) in comparison to the response of G carriers.
The main cognitive task of interest in this study is the N-back task because of the observed
attenuation of prefrontal and parietal cortical activity after nimodipine administration in
healthy subjects. Investigators hypothesize that acute nimodipine administration will improve
cortical activation, which will lead to improved cognitive performance. The current study
will provide insight whether nimodipine or another calcium channel blocker could be used as a
treatment approach to alleviate cognitive deficits in patients with schizophrenia.
attenuation of prefrontal and parietal cortical activity after nimodipine administration in
healthy subjects. Investigators hypothesize that acute nimodipine administration will improve
cortical activation, which will lead to improved cognitive performance. The current study
will provide insight whether nimodipine or another calcium channel blocker could be used as a
treatment approach to alleviate cognitive deficits in patients with schizophrenia.
Inclusion Criteria:
- This study will recruit patients with schizophrenia and/or schizoaffective disorder
Exclusion Criteria:
- past or current neurological disorder (including stroke, brain tumor, epilepsy,
Alzheimer's, Parkinson's or Huntington's disease)
- uncontrolled medical disorder
- current or past hypotension
- head trauma with loss of consciousness in the last year or any evidence of functional
impairment due to and persisting after head trauma
- positive pregnancy test, or currently breast feeding
- having an adverse reaction to nimodipine, or other calcium channel blocker
We found this trial at
2
sites
Johns Hopkins University The Johns Hopkins University opened in 1876, with the inauguration of its...
Click here to add this to my saved trials
Johns Hopkins Bayview Medical Center There is no better story in American medicine in the...
Click here to add this to my saved trials